Safety of biosimilar filgrastim in patients with breast cancer undergoing neutropenia-inducing chemotherapy: A subanalysis of the NEXT study.

被引：0
|
作者：
Lepretre, Stephane
Maloisel, Frederic
Kamioner, Didier
Berthou, Christian
Albrand, Helene
机构：
[1] Henri Becquerel Hosp, Rouen, France
[2] Clin St Anne, Strasbourg, France
[3] Hop Prive Ouest Parisien, Trappes, France
[4] Hop Morvan, Brest, France
[5] Hospira France, Meudon La Fort, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e20711
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Biosimilar filgrastim in the treatment of patients with breast cancer undergoing neutropenia-inducing chemotherapy: A subanalysis of the NEXT study
    Albrand, H.
    Kamioner, D.
    Lepretre, S.
    [J]. CANCER RESEARCH, 2016, 76
  • [2] Safety of biosimilar filgrastim in elderly patients undergoing neutropenia-inducing chemotherapy: a subanalysis of the NEXT study
    Kamioner, Didier
    Maloisel, Frederic
    Lepretre, Stephane
    Berthou, Christian
    Albrand, Helene
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [3] SAFETY OF BIOSIMILAR FILGRASTIM IN PATIENTS WITH LYMPHOMA AND MYELOMA UNDERGOING NEUTROPENIA-INDUCING CHEMOTHERAPY: A SUBANALYSIS OF THE NEXT STUDY
    Lepretre, S.
    Maloisel, F.
    Kamioner, D.
    Berthou, C.
    Albrand, H.
    [J]. HAEMATOLOGICA, 2015, 100 : 469 - 469
  • [4] Safety of Biosimilar Filgrastim in Patients with Haematological Malignancies Undergoing Neutropenia-Inducing Chemotherapy: A Subanalysis of the Next Study
    Lepretre, Stephane
    Maloisel, Frederic
    Kamioner, Didier
    Berthou, Christian
    Albrand, Helene
    [J]. BLOOD, 2014, 124 (21)
  • [5] Safety of Biosimilar Filgrastim in Patients Undergoing Neutropenia-Inducing Chemotherapy: The Next Study
    Lepretre, Stephane
    Maloisel, Frederic
    Kamioner, Didier
    Berthou, Christian
    Albrand, Helene
    [J]. BLOOD, 2014, 124 (21)
  • [6] Safety and efficacy of prophylactic and curative biosimilar filgrastim in patients undergoing neutropenia-inducing chemotherapy: The NEXT study
    Maloisel, F.
    Lepretre, S.
    Kamioner, D.
    Berthou, C.
    Albrand, H.
    [J]. EUROPEAN JOURNAL OF CANCER, 2015, 51 : S243 - S243
  • [7] Safety of biosimilar filgrastim in patients with lymphoma undergoing neutropenia-inducing chemotherapy: a sub-analysis of the NEXT study
    Lepretre, S.
    Maloisel, F.
    Kamioner, D.
    Berthou, C.
    Albrand, H.
    [J]. BONE MARROW TRANSPLANTATION, 2015, 50 : 5623 - 5624
  • [8] Safety and efficacy of biosimilar filgrastim in patients with colorectal cancer undergoing neutropenia-inducing chemotherapy: A sub-analysis of the NEXT study
    Kamioner, D.
    Lepretre, S.
    Maloisel, F.
    Berthou, C.
    Albrand, H.
    [J]. EUROPEAN JOURNAL OF CANCER, 2015, 51 : S242 - S242
  • [9] Safety and efficacy of biosimilar filgrastim in patients with lung cancer undergoing neutropenia-inducing chemotherapy: A sub-analysis of the NEXT study
    Kamioner, D.
    Lepretre, S.
    Maloisel, F.
    Berthou, C.
    Albrand, H.
    [J]. EUROPEAN JOURNAL OF CANCER, 2015, 51 : S204 - S205
  • [10] BIOSIMILAR FILGRASTIM IN PATIENTS UNDERGOING NEUTROPENIA-INDUCING CHEMOTHERAPY: OVERALL RESULTS FROM THE NEXT OBSERVATIONAL STUDY
    Maloisel, F.
    Lepretre, S.
    Kamioner, D.
    Christian, B.
    Albrand, H.
    [J]. HAEMATOLOGICA, 2015, 100 : 470 - 470
12345